Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Lauderhill, South Carolina Clinical Trials

A listing of Lauderhill, South Carolina clinical trials actively recruiting patient volunteers.

RESULTS

Found (11) clinical trials

A Phase Ib Study to Evaluate the Safety Tolerability and Pharmacokinetics (PK) of Avelumab in Combination With M9241(NHS-IL12) (JAVELIN IL-12)

The study consists of 2 parts: Dose Escalation phase (Part A) and Expansion phase (Part B). The dose escalation phase will evaluate the safety, tolerability, and PK of avelumab in combination with M9241 in subjects with locally advanced, unresectable, or metastatic solid tumors. Expansion phase will assess the safety and ...

Phase

1.21 miles

Learn More »

Study to Evaluate the Pharmacokinetics Pharmacodynamics and Safety of Vadadustat in Hemodialysis Subjects With Anemia Associated With Chronic Kidney Disease

This study will be conducted to assess the pharmacokinetics of vadadustat 600, 750, and 900 milligrams daily, and intravenous erythropoiesis-stimulating agent (darbepoetin alfa or epoetin alfa), in hemodialysis participants with anemia associated with chronic kidney disease.

Phase

1.21 miles

Learn More »

Evaluating the Safety and Pharmacokinetics of VRC01 VRC01LS and VRC07-523LS Potent Anti-HIV Neutralizing Monoclonal Antibodies in HIV-1-Exposed Infants

VRC01, VRC01LS, and VRC07-523LS are anti-HIV neutralizing monoclonal antibodies that may help prevent mother-to-child transmission of HIV. This study will enroll HIV-infected mothers who are at increased risk of passing HIV on to their children. The purpose of this study is to assess the safety and PK of VRC01, VRC01LS, ...

Phase

3.97 miles

Learn More »

A Study to Evaluate the Safety Pharmacokinetics (PK) and Pharmacodynamics (PD) of TAK-079 in Combination With Standard Background Therapy in Participants With Moderate to Severe Systemic Lupus Erythematosus (SLE)

TAK-079 is being tested in a study population with moderate to severe SLE. This study will evaluate the safety and biologic activity of TAK-079 or matching placebo in combination with stable SLE background therapy. The study will enroll approximately 24 participants across 3 sequentially enrolling cohorts. Each cohort will enroll ...

Phase

4.7 miles

Learn More »

A Study to Evaluate VIB7734 in Participants With Systemic Lupus Erythematosus (SLE) Cutaneous Lupus Erythematosus (CLE) Sjogren's Syndrome Systemic Sclerosis Polymyositis and Dermatomyositis

This study will have 3 periods: screening, treatment period, and extended follow-up. The screening period is 28 days. A total of 32 participants will be enrolled in 3 cohorts with 8 participants in Cohort 1, and 12 participants each in Cohorts 2 and 3. In Cohort 1, participants will be ...

Phase

4.7 miles

Learn More »

End-stage Renal Disease (ESRD) Pilot Study

The purpose of this study is to investigate the safety of two different doses of a drug called BAY1213790 and how well it is tolerated in patients with end-stage renal disease (ESRD) undergoing hemodialysis (HD). Approximately 40, with up to 60 study patients will take part in the study.

Phase

5.8 miles

Learn More »

Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors

This study will evaluate palbociclib in combination with chemotherapy (temozolomide and irinotecan) in children, adolescents and young adults with recurrent or refractory solid tumors. The main purpose of this study is to evaluate the safety of palbociclib in combination with chemotherapy in order to estimate the maximum tolerated dose. Pharmacokinetics ...

Phase

6.43 miles

Learn More »

HEPLISAV-B in Adults With End-Stage Renal Disease (ESRD) Undergoing Hemodialysis

Eligible participants will receive single doses of HEPLISAV-B at Weeks 0, 4, 8, and 16 and will be followed through Week 68 or end of study (EOS). The study is designed to evaluate the immunogenicity and safety over a 68-week period.

Phase

6.59 miles

Learn More »

A Phase 1 Study of Ruxolitinib Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients

Multiple myeloma (MM), a plasma cell dyscrasia, is the most common primary malignancy of the bone marrow.The etiology of myeloma is largely unknown, although genetic predisposition and environmental factors have been speculated. MM arises from malignant plasma cells that clonally expand and accumulate in the bone marrow. These clonal plasma ...

Phase

6.93 miles

Learn More »

Study of TAK-925 in Participants With Obstructive Sleep Apnea (OSA) Who Are Experiencing Excessive Daytime Sleepiness (EDS) Despite Adequate Use of Continuous Positive Airway Pressure (CPAP)

The drug being tested in this study is called TAK-925. TAK-925 is being tested to treat participants who have EDS due to OSA despite using CPAP. The study will evaluate the pharmacokinetics (PK), pharmacodynamics (PD), safety, and tolerability of a single IV dose of TAK-925 in participants with OSA. The ...

Phase

6.97 miles

Learn More »